Cargando…
Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study
The simultaneous use of multiple drugs—termed ‘polypharmacy’—is often required to manage multiple physiological and biological changes and the interplay between chronic disorders that are expected to increase in association with ageing. However, by increasing the number of medications consumed, the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299180/ https://www.ncbi.nlm.nih.gov/pubmed/37373654 http://dx.doi.org/10.3390/jcm12123960 |
_version_ | 1785064299856658432 |
---|---|
author | Alhumaidi, Reham M. Bamagous, Ghazi A. Alsanosi, Safaa M. Alqashqari, Hamsah S. Qadhi, Rawabi S. Alhindi, Yosra Z. Ayoub, Nahla Falemban, Alaa H. |
author_facet | Alhumaidi, Reham M. Bamagous, Ghazi A. Alsanosi, Safaa M. Alqashqari, Hamsah S. Qadhi, Rawabi S. Alhindi, Yosra Z. Ayoub, Nahla Falemban, Alaa H. |
author_sort | Alhumaidi, Reham M. |
collection | PubMed |
description | The simultaneous use of multiple drugs—termed ‘polypharmacy’—is often required to manage multiple physiological and biological changes and the interplay between chronic disorders that are expected to increase in association with ageing. However, by increasing the number of medications consumed, the risk of undesirable medication reactions and drug interactions also increases exponentially. Hence, knowledge of the prevalence of polypharmacy and the risk of potentially serious drug–drug interactions (DDIs) in elderly patients should be considered a key topic of interest for public health and health care professionals. Methods: Prescription and demographic data were collected from the electronic files of patients who were aged ≥ 65 years and attended Al-Noor Hospital in Makkah, Saudi Arabia, between 2015 and 2022. The Lexicomp(®) electronic DDI-checking platform was used to evaluate the patients’ medication regimens for any potential drug interactions. Results: A total of 259 patients were included in the study. The prevalence of polypharmacy among the cohort was 97.2%: 16 (6.2%) had minor polypharmacy, 35 (13.5%) had moderate polypharmacy, and 201 (77.6%) had major polypharmacy. Of the 259 patients who were taking two or more medications simultaneously, 221 (85.3%) had at least one potential DDI (pDDI). The most frequently reported pDDI under category X that should be avoided was the interaction between clopidogrel and esomeprazole and was found in 23 patients (18%). The most frequently reported pDDI under category D that required therapeutic modification was the interaction between enoxaparin and aspirin, which was found in 28 patients (12%). Conclusions: It is often necessary for elderly patients to take several medications simultaneously to manage chronic diseases. Clinicians should distinguish between suitable, appropriate and unsuitable, inappropriate polypharmacy, and this criterion should be closely examined when establishing a therapeutic plan. |
format | Online Article Text |
id | pubmed-10299180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102991802023-06-28 Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study Alhumaidi, Reham M. Bamagous, Ghazi A. Alsanosi, Safaa M. Alqashqari, Hamsah S. Qadhi, Rawabi S. Alhindi, Yosra Z. Ayoub, Nahla Falemban, Alaa H. J Clin Med Brief Report The simultaneous use of multiple drugs—termed ‘polypharmacy’—is often required to manage multiple physiological and biological changes and the interplay between chronic disorders that are expected to increase in association with ageing. However, by increasing the number of medications consumed, the risk of undesirable medication reactions and drug interactions also increases exponentially. Hence, knowledge of the prevalence of polypharmacy and the risk of potentially serious drug–drug interactions (DDIs) in elderly patients should be considered a key topic of interest for public health and health care professionals. Methods: Prescription and demographic data were collected from the electronic files of patients who were aged ≥ 65 years and attended Al-Noor Hospital in Makkah, Saudi Arabia, between 2015 and 2022. The Lexicomp(®) electronic DDI-checking platform was used to evaluate the patients’ medication regimens for any potential drug interactions. Results: A total of 259 patients were included in the study. The prevalence of polypharmacy among the cohort was 97.2%: 16 (6.2%) had minor polypharmacy, 35 (13.5%) had moderate polypharmacy, and 201 (77.6%) had major polypharmacy. Of the 259 patients who were taking two or more medications simultaneously, 221 (85.3%) had at least one potential DDI (pDDI). The most frequently reported pDDI under category X that should be avoided was the interaction between clopidogrel and esomeprazole and was found in 23 patients (18%). The most frequently reported pDDI under category D that required therapeutic modification was the interaction between enoxaparin and aspirin, which was found in 28 patients (12%). Conclusions: It is often necessary for elderly patients to take several medications simultaneously to manage chronic diseases. Clinicians should distinguish between suitable, appropriate and unsuitable, inappropriate polypharmacy, and this criterion should be closely examined when establishing a therapeutic plan. MDPI 2023-06-10 /pmc/articles/PMC10299180/ /pubmed/37373654 http://dx.doi.org/10.3390/jcm12123960 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Alhumaidi, Reham M. Bamagous, Ghazi A. Alsanosi, Safaa M. Alqashqari, Hamsah S. Qadhi, Rawabi S. Alhindi, Yosra Z. Ayoub, Nahla Falemban, Alaa H. Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study |
title | Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study |
title_full | Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study |
title_fullStr | Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study |
title_full_unstemmed | Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study |
title_short | Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study |
title_sort | risk of polypharmacy and its outcome in terms of drug interaction in an elderly population: a retrospective cross-sectional study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299180/ https://www.ncbi.nlm.nih.gov/pubmed/37373654 http://dx.doi.org/10.3390/jcm12123960 |
work_keys_str_mv | AT alhumaidirehamm riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy AT bamagousghazia riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy AT alsanosisafaam riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy AT alqashqarihamsahs riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy AT qadhirawabis riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy AT alhindiyosraz riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy AT ayoubnahla riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy AT falembanalaah riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy |